TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:05
Adicet Bio Inc. ( ACET ) https://www.adicetbio.com
0.96USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-44.83%
ACET
SPY
32.66%
-93.78%
ACET
SPY
108.59%
-89.61%
ACET
SPY
302.52%
ACET
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
87.21
-96.65
0.32
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.74
1.86
0.41
-73.17
0.00
0.78
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-239.42
-12.80
-239.63
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
11.6064
-49.15
-52.12
1.98
Other Earnings and Cash Flow Stats:
Adicet Bio Inc. ( ACET ) Net Income TTM ($MM) is -117.88
Adicet Bio Inc. ( ACET ) Operating Income TTM ($MM) is -128.44
Adicet Bio Inc. ( ACET ) Owners' Earnings Annual ($MM) is 0.00
Adicet Bio Inc. ( ACET ) Current Price to Owners' Earnings ratio is 0.00
Adicet Bio Inc. ( ACET ) EBITDA TTM ($MM) is -121.90
Adicet Bio Inc. ( ACET ) EBITDA Margin is -239.63%
Capital Allocation:
Adicet Bio Inc. ( ACET ) has paid 0.00 dividends per share and bought back -47.865652 million shares in the past 12 months
Adicet Bio Inc. ( ACET ) has reduced its debt by 3.598 million USD in the last 12 months
Capital Structure:
Adicet Bio Inc. ( ACET ) Interest-bearing Debt ($MM) as of last quarter is 18
Adicet Bio Inc. ( ACET ) Annual Working Capital Investments ($MM) are -8
Adicet Bio Inc. ( ACET ) Book Value ($MM) as of last quarter is 211
Adicet Bio Inc. ( ACET ) Debt/Capital as of last quarter is 8%
Other Balance Sheet Stats:
Adicet Bio Inc. ( ACET ) has 105 million in cash on hand as of last quarter
Adicet Bio Inc. ( ACET ) has 19 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Adicet Bio Inc. ( ACET ) has 90 common shares outstanding as of last quarter
Adicet Bio Inc. ( ACET ) has 0 million USD of preferred stock value
Academic Scores:
Adicet Bio Inc. ( ACET ) Altman Z-Score is -1.77 as of last quarter
Adicet Bio Inc. ( ACET ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Adicet Bio Inc. ( ACET ) largest shareholder is owning shares at 0.00 ($MM) value
Kauffman Michael(an insider) Sold 5900 shares of Adicet Bio Inc. ( ACET ) for the amount of $8437.00 on 2024-06-05
1.59% of Adicet Bio Inc. ( ACET ) is held by insiders, and 76.44% is held by institutions
Adicet Bio Inc. ( ACET ) went public on 2018-01-26
Other Adicet Bio Inc. ( ACET ) financial metrics:
FCF:-92.84
Unlevered Free Cash Flow:0.00
EPS:-1.34
Operating Margin:-239.42
Gross Profit Margin:-12.80
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-57.63
Beta:1.98
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Adicet Bio Inc. ( ACET ) :
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.